Parallax Volatility Advisers’s Jazz Pharmaceuticals JAZZ Stock Holding History

Parallax Volatility Advisers’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-14	Closed	-$2K	–	2947
2019 Q2	$2K	Sell	14 -2,087	-99%	-$280K	﹤0.01%	2386
2019 Q1	$300K	Sell	2,101 -52,466	-96%	-$6.84M	﹤0.01%	1713
2018 Q4	$6.76M	Buy	54,567 +42,292	+345%	+$6.27M	0.01%	635
2018 Q3	$2.06M	Buy	+12,275	New	+$2.11M	﹤0.01%	1012
2018 Q1	–	Sell	-12,246	Closed	-$1.65M	–	3298
2017 Q4	$1.65M	Buy	12,246 +4,318	+54%	+$599K	﹤0.01%	990
2017 Q3	$1.16M	Buy	+7,928	New	+$1.2M	﹤0.01%	1022
2017 Q1	–	Sell	-12,500	Closed	-$1.63M	–	4156
2016 Q4	$1.36M	Buy	12,500 +2,243	+22%	+$250K	﹤0.01%	1110
2016 Q3	$1.25M	Buy	+10,257	New	+$1.38M	﹤0.01%	1169
2016 Q2	–	Sell	-2,418	Closed	-$316K	–	3079
2016 Q1	$316K	Buy	2,418 +1,518	+169%	+$189K	﹤0.01%	1610
2015 Q4	$127K	Buy	+900	New	+$125K	﹤0.01%	2048

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Parallax Volatility Advisers's JAZZ Position: Q3 2019 in Review

Parallax Volatility Advisers sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2019, closing a stake of 14 shares — an estimated $2K sold.

Parallax Volatility Advisers first reported a position in JAZZ in Q4 2015 and held it in 10 quarters. The position peaked at $6.76M in Q4 2018. 406 funds tracked by Wall St. Rank hold JAZZ as of Q3 2019.

Parallax Volatility Advisers reported no remaining Jazz Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Parallax Volatility Advisers sold 14 Jazz Pharmaceuticals shares in Q3 2019, an estimated $2K.
Parallax Volatility Advisers first reported a position in Jazz Pharmaceuticals in Q4 2015 and held it in 10 quarters.
Parallax Volatility Advisers's Jazz Pharmaceuticals position peaked at $6.76M in Q4 2018.
406 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2019.

Based on Parallax Volatility Advisers's 13F filing for Q3 2019, filed 14 Nov 2019.